Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan

Pimavanserin

  • Efrain Antonio GonzalezEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_9272

Generic Name

Pimavanserin

Brand Name

Nuplazid

Class

Antipsychotics, second generation

Proposed Mechanism(s) of Action

Inverse agonist and antagonist activity at the serotonin 5-HT2A receptors, and some antagonist activity at the serotonin 5-HT2C receptors.

Indication

For the treatment of hallucinations and delusions associated with Parkinson’s disease.

Off-Label Use

Bipolar maintenance, bipolar depression, and behavioral disturbances in the elderly and children.

Side Effects

Serious

Increased risk of death in elderly patients with dementia-related psychosis; Q-T interval prolongation.

Common

Peripheral edema, nausea, confusion, hallucination, constipation, and gait disturbance.

References and Readings

  1. Physicians’ desk reference (71st ed.) (2017). Montvale: Thomson PDR.Google Scholar

Additional Information

  1. Free Drug Online and PDA Software. www.epocrates.com
  2. Free Drug Online and PDA Software. www.medscape.com

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of PsychologyNova Southeastern UniversityFort LauderdaleUSA
  2. 2.Utah State UniversityLoganUSA